Literature DB >> 22462748

Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Jing Li1, Vincent Menard, Rebekah L Benish, Richard J Jurevic, Chantal Guillemette, Mark Stoneking, Peter A Zimmerman, Rajeev K Mehlotra.   

Abstract

AIM: Hepatic enzymes, CYP2B6 and UGT2B7 play a major role in the metabolism of the widely used antiretroviral drugs efavirenz, nevirapine and zidovudine. In the present study, we provide a view of UGT2B7 haplotype structure, and quantify the genetic diversity and differentiation at both CYP2B6 and UGT2B7 genes on a worldwide scale. MATERIALS &
METHODS: We genotyped one intronic and three promoter SNPs, and together with three nonsynonymous SNPs, inferred UGT2B7 alleles in north American (n = 326), west African (n = 133) and Papua New Guinean (n = 142) populations. We also included genotype data for five CYP2B6 and six UGT2B7 SNPs from an additional 12 worldwide populations (n = 629) analyzed in the 1000 Genomes Project.
RESULTS: We observed significant differences in certain SNP and allele frequencies of CYP2B6 and UGT2B7 among worldwide populations. Diversity values were higher for UGT2B7 than for CYP2B6, although there was more diversity between populations for CYP2B6. For both genes, most of the genetic variation was observed among individuals within populations, with the Papua New Guinean population showing the highest pairwise differentiation values for CYP2B6, and the Asian and European populations showing higher pairwise differentiation values for UGT2B7.
CONCLUSION: These new genetic distinctions provide additional insights for investigating differences in antiretroviral pharmacokinetics and therapy outcomes among ethnically and geographically diverse populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22462748      PMCID: PMC3390746          DOI: 10.2217/pgs.11.160

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  90 in total

1.  Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.

Authors:  Tristan Lindfelt; John O'Brien; Jessica C Song; Rajul Patel; Dean L Winslow
Journal:  Ann Pharmacother       Date:  2010-09-14       Impact factor: 3.154

2.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

3.  CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

4.  HIV and AIDS Data Hub for Asia Pacific: a regional tool to support strategic information needs.

Authors:  Amala Reddy; Khin Cho Win Htin; Ye Yu Shwe
Journal:  Western Pac Surveill Response J       Date:  2012-09-10

5.  Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.

Authors:  Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-06-09       Impact factor: 4.030

6.  Efavirenz intoxication due to slow hepatic metabolism.

Authors:  B Hasse; H F Günthard; G Bleiber; M Krause
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

7.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079

Review 8.  Modulation of UDP-glucuronosyltransferase activity by protein-protein association.

Authors:  Yuji Ishii; Shuso Takeda; Hideyuki Yamada
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

9.  Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

Authors:  Thanyawee Puthanakit; Pranoot Tanpaiboon; Linda Aurpibul; Tim R Cressey; Virat Sirisanthana
Journal:  Antivir Ther       Date:  2009

10.  Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.

Authors:  P J Easterbrook; A N Phillips; T Hill; R Matthias; M Fisher; B Gazzard; R Gilson; G Scullard; M Johnson; D T Dunn; C Orkin; J Anderson; A Schwenk; C Leen; C A Sabin
Journal:  HIV Med       Date:  2008-01       Impact factor: 3.180

View more
  30 in total

1.  The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.

Authors:  Li-Chen Gao; Fang-Qun Liu; Li Yang; Lin Cheng; Hai-Ying Dai; Ran Tao; Shi-Peng Cao; Di Wang; Jie Tang
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

Review 2.  Human Genetic Variation and HIV/AIDS in Papua New Guinea: Time to Connect the Dots.

Authors:  Rajeev K Mehlotra
Journal:  Curr HIV/AIDS Rep       Date:  2018-12       Impact factor: 5.071

3.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Authors:  Daniel Atwine; Maryline Bonnet; Anne-Marie Taburet
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

4.  Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Authors:  Doo-Yeoun Cho; Joan H Q Shen; Suzanne M Lemler; Todd C Skaar; Lang Li; Julia Blievernicht; Ulrich M Zanger; Kwon-Bok Kim; Jae-Gook Shin; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2015-07-29       Impact factor: 3.614

Review 5.  Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

Authors:  Rowena E Johnston; Mary M Heitzeg
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 6.  Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.

Authors:  Panjasaram Naidoo; Vasudevan V Chetty; Manoranjenni Chetty
Journal:  Eur J Clin Pharmacol       Date:  2014-01-05       Impact factor: 2.953

Review 7.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

8.  CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.

Authors:  Carola R Röhrich; Britt I Drögemöller; Ogechi Ikediobi; Lize van der Merwe; Nelis Grobbelaar; Galen E B Wright; Nathaniel McGregor; Louise Warnich
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

9.  Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.

Authors:  Ahmed M Abdelhady; Tyler Shugg; Nancy Thong; Jessica Bo Li Lu; Yvonne Kreutz; Heather A Jaynes; Jason D Robarge; James E Tisdale; Zeruesenay Desta; Brian R Overholser
Journal:  J Cardiovasc Electrophysiol       Date:  2016-07-25

Review 10.  EFV/FTC/TDF-associated hepatotoxicity: a case report and review.

Authors:  Ignacio A Echenique; Josiah D Rich
Journal:  AIDS Patient Care STDS       Date:  2013-08-12       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.